Novo Nordisk A/S
(NYSE:NVO)
$
135.452
0.172 (0.13%)
Market Cap: 603.37 Bil
Enterprise Value: 606.51 Bil
PE Ratio: 46.87
PB Ratio: 41.94
GF Score: 92/100 
Q1 2024 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 03, 2024$123.05 (-0.78%)Earnings- Q1 2024 Novo Nordisk A/S Earnings Call TranscriptMay 02, 2024$124.02 (-4.02%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2024
- Novo Nordisk A/S Capital Markets Day TranscriptMar 07, 2024
- Q4 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 01, 2024$115.79 (+0.92%)Earnings
- Q4 2023 Novo Nordisk A/S Earnings Call TranscriptJan 31, 2024$114.74 (+5.25%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Novo Nordisk A/S at American Heart Association Conference TranscriptNov 11, 2023
- Q3 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2023$98.17 (-2.73%)Earnings
- Q3 2023 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2023$100.93 (+3.33%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 11, 2023$90.8 (-0.27%)Earnings
- Q2 2023 Novo Nordisk A/S Earnings Call TranscriptAug 10, 2023$91.05 (-2.93%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 26, 2023
- Q1 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 09, 2023$84.27 (+0.05%)Earnings
- Q1 2023 Novo Nordisk A/S Earnings Call TranscriptMay 04, 2023$80.22 (-4.38%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 23, 2023
- Q4 2022 Novo Nordisk A/S Earnings Call TranscriptFeb 01, 2023$69.54 (+0.22%)Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 03, 2022$56.94 (+0.57%)Earnings
- Q3 2022 Novo Nordisk A/S Earnings Call TranscriptNov 02, 2022$56.62 (+6.39%)Earnings
- Novo Nordisk A/S at JPMorgan CEO Call Series TranscriptSep 14, 2022
- Q2 2022 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 05, 2022$51.6 (-1.22%)Earnings
- Q2 2022 Novo Nordisk A/S Earnings Call TranscriptAug 03, 2022$49.96 (-12.71%)Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA TranscriptJun 06, 2022
- Q1 2022 Novo Nordisk A/S Earnings Presentation - London TranscriptMay 05, 2022
- Q1 2022 Novo Nordisk A/S Earnings Call TranscriptApr 29, 2022$57 (+3.46%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 24, 2022
- Novo Nordisk A/S Capital Markets Day TranscriptMar 03, 2022
- Q4 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 04, 2022$49.84 (-4.74%)Earnings
- Q4 2021 Novo Nordisk A/S Earnings Call TranscriptFeb 02, 2022$53.3 (+3.89%)Earnings
- Novo Nordisk A/S to Discuss Supply Challenges for Wegovy Call TranscriptDec 20, 2021
- Q3 2021 Novo Nordisk A/S Earnings Presentation (London-Based Investors) TranscriptNov 04, 2021
- Q3 2021 Novo Nordisk A/S Earnings Call TranscriptNov 03, 2021$57.78 (+5.01%)Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 06, 2021$49.74 (-3.51%)Earnings
- Q2 2021 Novo Nordisk A/S Earnings Call TranscriptAug 04, 2021$49.11 (+5.47%)Earnings
- Novo Nordisk A/S R&D Investor Call TranscriptJun 28, 2021
- Novo Nordisk A/S Approval of Wegovy™ in the United States Investor Call TranscriptJun 07, 2021
- Novo Nordisk A/S to Discuss International Operations Call TranscriptMay 21, 2021
- Q1 2021 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptMay 06, 2021$37.1 (+0.18%)Earnings
- Q1 2021 Novo Nordisk A/S Earnings Call TranscriptMay 05, 2021$37.04 (-0.08%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 25, 2021
- Q4 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptFeb 05, 2021$35.7 (-0.32%)Earnings
- Q4 2020 Novo Nordisk A/S Earnings Call TranscriptFeb 03, 2021$36.21 (+2.03%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference (Virtual) TranscriptJan 12, 2021
- Novo Nordisk A/S to Announce the Decision to Enter the Phase 3 Development in Alzheimer's Disease with Oral Semaglutide Call TranscriptDec 16, 2020
- Novo Nordisk A/S ESG Conference Call TranscriptNov 30, 2020
- Q3 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptNov 02, 2020$32.52 (+1.78%)Earnings
- Q3 2020 Novo Nordisk A/S Earnings Call TranscriptOct 30, 2020$31.95 (-3.68%)Earnings
- Novo Nordisk A/S to Discuss Updated 2020 Outlook Call TranscriptOct 09, 2020
- Q2 2020 Novo Nordisk A/S Earnings Call (London-Based Investors) TranscriptAug 07, 2020$32.32 (+1.49%)Earnings
- Q2 2020 Novo Nordisk A/S Earnings Call TranscriptAug 06, 2020$31.85 (-2.15%)Earnings
- Novo Nordisk A/S Virtual R&D Investor Call (Q&A) TranscriptJun 19, 2020
- Novo Nordisk A/S Virtual R&D Investor Presentation TranscriptJun 19, 2020
- Novo Nordisk A/S at UBS Global Healthcare Conference (Virtual) TranscriptMay 20, 2020
- Q1 2020 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2020
- Q1 2020 Novo Nordisk A/S Earnings Call TranscriptMay 06, 2020$30.99 (-1.82%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 26, 2020
- Q4 2019 Novo Nordisk A/S Earnings Presentation TranscriptFeb 06, 2020
- Q4 2019 Novo Nordisk A/S Earnings Call TranscriptFeb 05, 2020$32.21 (+4.58%)Earnings
- Novo Nordisk A/S at JPMorgan Healthcare Conference TranscriptJan 14, 2020
- Novo Nordisk A/S Capital Markets Day TranscriptNov 20, 2019
- Dicerna Pharmaceuticals Inc to Discuss Collaboration with Novo Nordisk A/S Conference Call TranscriptNov 18, 2019
- Q3 2019 Novo Nordisk A/S Earnings Presentation TranscriptNov 04, 2019
- Q3 2019 Novo Nordisk A/S Earnings Call TranscriptNov 01, 2019$28.23 (+2.25%)Earnings
- Novo Nordisk A/S to Discuss Rybelsus® US Approval Call TranscriptSep 23, 2019
- Q2 2019 Novo Nordisk A/S Earnings Presentation TranscriptAug 12, 2019
- Q2 2019 Novo Nordisk A/S Earnings Call TranscriptAug 09, 2019$25.14 (-0.79%)Earnings
- Novo Nordisk A/S Investor and Analyst Event at ADA 2019 TranscriptJun 10, 2019
- Q1 2019 Novo Nordisk A/S Earnings Presentation TranscriptMay 07, 2019
- Q1 2019 Novo Nordisk A/S Earnings Call TranscriptMay 03, 2019$23.75 (-2.82%)Earnings
- Novo Nordisk A/S Annual Shareholders Meeting TranscriptMar 21, 2019
Novo Nordisk A/S Approval of Wegovy™ in the United States Investor Call Transcript
Jun 07, 2021 / 06:30AM GMT
Release Date Price:
$40.6
(+0.31%)
Operator
Hello, and welcome to the Novo Nordisk A/S conference call. (Operator Instructions) Today, I'm pleased to present Karsten Munk Knudsen. Please go ahead with your meeting.
Karsten Munk Knudsen;S;Executive VP
Novo Nordisk A;CFO & Member of the Management Board
/- -
Thank you. Welcome to the Novo Nordisk investor conference call covering the approval of semaglutide 2.4 in the U.S. now known under the brand name of Wegovy. My name is Karsten Munk Knudsen. I'm the CFO of Novo Nordisk. And today, with me, I have EVP of Commercial Strategy & Corporate Affairs, Camilla Sylvest; and EVP of Development, Martin Lange.
We will be doing a brief presentation followed by a Q&A, where we will only do 1 question per person since we have a fairly short time period today.
So today, we also might run into forward-looking statements. And as you know, by their very nature, these statements are subject to risks and uncertainties, and final outcomes might turn out differently.
The starting point for the
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers